05/07/2026
New research is here! Dr. Houman Farzin, Mystic’s Founder and Chief Medical Officer, has co-authored new research published in Neuroscience & Biobehavioral Reviews exploring how psych-d-lics may influence epigenetic pathways involved in Alzheimer’s disease.
The review looks at how these compounds may support neuroplasticity, modulate biological processes linked to cognitive decline, and potentially help counter some of the dysregulation underlying disease progression. It opens an exciting new conversation about psych-d-lics not only as tools for brain health, but as a possible avenue for addressing Alzheimer’s at a deeper mechanistic level. đź§
Read the full publication at the link in our bio. đź”—